AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts see $5.8bn price tag for the privately held biotech as likely too high, but AbbVie is bullish on lead antibody-drug conjugate's potential in lung cancer. Focus on the acquisition shifted attention during the quarterly earnings call from disappointing sales for Viekira.
You may also be interested in...
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.